Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a clinical-stage biopharmaceutical company pioneering monoclonal antibody (mAb) therapies to combat evolving viral threats like COVID-19. This page provides investors and stakeholders with timely updates on Invivyd’s regulatory milestones, clinical trial progress, and strategic initiatives.
Discover the latest developments for PEMGARDA™, Invivyd’s EUA-authorized pre-exposure prophylaxis, and next-generation candidates like VYD2311. Our news collection covers critical updates including FDA communications, partnership announcements, and peer-reviewed data publications. All content is vetted for accuracy and relevance to ensure you stay informed on Invivyd’s progress in protecting immunocompromised populations.
Key focus areas include advancements from the proprietary INVYMAB™ platform, trial results demonstrating variant resistance, and manufacturing scalability updates. Bookmark this page for direct access to press releases, earnings call summaries, and analyses of Invivyd’s role in infectious disease innovation.
Invivyd (Nasdaq: IVVD) priced an underwritten public offering totaling approximately $125.0 million in gross proceeds on Nov 18, 2025. The offering comprises 44,000,000 shares of common stock at $2.50 per share and, to certain investors, 6,000,000 pre-funded warrants at $2.4999 each (exercise price $0.0001). The company granted underwriters a 30-day option to buy up to 7,500,000 additional shares. Closing is expected on or about Nov 19, 2025, subject to customary conditions.
Invivyd said net proceeds will fund commercial preparedness for potential launch of VYD2311, continued R&D (including RSV and measles programs), SPEAR Study Group work on monoclonal antibody effects in Long COVID and COVID-19 post-vaccination syndrome, and general corporate purposes. Cantor is sole book-running manager and H.C. Wainwright is lead manager. The offering is made from a shelf registration on Form S-3 (File No. 333-267643).
Invivyd (Nasdaq: IVVD) on November 17, 2025 announced an underwritten public offering of shares of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of the shares sold. All shares are being offered by Invivyd and the offering is subject to market conditions; timing, size and terms are not assured.
The company said it intends to use net proceeds, together with existing cash, for commercial preparedness for VYD2311, continued R&D for RSV and measles programs, SPEAR Study Group efforts on monoclonal antibody effects for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and general corporate purposes.
Invivyd (NASDAQ: IVVD) reported Q3 2025 PEMGARDA net product revenue of $13.1M, up 41% YoY and 11% QoQ. The company ended Q3 with $85.0M cash and reported October 2025 ending cash of over $100M after raising proceeds from a $57.5M public offering and $29.8M ATM sales. Invivyd received FDA IND clearance and alignment for its REVOLUTION pivotal program for VYD2311, with two Phase 3 trials planned (DECLARATION, n=1,770; LIBERTY, n=210) and top-line data expected mid-2026. Q3 R&D expense fell to $8.0M from $57.9M a year earlier; SG&A was $15.0M. Net loss narrowed to $10.5M (Q3 2025).
Invivyd (Nasdaq: IVVD) will host a conference call on Thursday, November 6, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide a corporate update.
Interested parties may join the live webcast via the company's investor relations site and are advised to log in about 15 minutes before the start. A recording will be available on the investor relations website shortly after the event.
Invivyd (Nasdaq: IVVD) will host a live webcast on Thursday, October 30, 2025 at 8:30 a.m. ET to present an overview of the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody candidate to prevent COVID.
Key presenters include Marc Elia (Chairman), Tim Lee (Chief Commercial Officer), Robert Allen, PhD (Chief Scientific Officer), and Mark Wingertzahn, PhD (SVP, Clinical Development). Listeners should join the webcast link 15 minutes before start; a replay will be posted to the company investor relations website about two hours after the call ends.
Invivyd (NASDAQ: IVVD) announced U.S. FDA clearance of its IND and alignment on the REVOLUTION clinical program for VYD2311, a vaccine‑alternative monoclonal antibody to prevent COVID. The company plans two trials: DECLARATION (Phase 3, BLA‑enabling, ~2,000 participants; single IM dose and monthly dosing arms) and LIBERTY (active‑controlled safety/tolerability vs. mRNA vaccine, ~300 participants with co‑administration arm subject to final FDA alignment). Trials aim to start around year‑end 2025 with top‑line data anticipated mid‑2026. Invivyd says commercial launch quantities are available and trials are funded by a recent capital raise.
Invivyd (NASDAQ: IVVD) has appointed Dr. Paul B. Bolno to its Board of Directors and Compensation Committee. Dr. Bolno, who currently serves as President and CEO of Wave Life Sciences, brings extensive experience in pipeline development and technological platforms for creating new medical products.
The appointment comes as Invivyd focuses on developing solutions for viral infectious diseases, particularly in the areas of COVID-19 prevention and treatment. Dr. Bolno also serves on the Board of ExpressionEdits and chairs the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.
Invivyd (Nasdaq: IVVD) has appointed Kristie Kuhl as Chief Communications Officer to lead the company's communications and patient advocacy initiatives. Kuhl, recognized in PRWeek's 2024 Health Influencer 30, joins from Zeno Group where she served as Global Managing Director of Health & Wellness.
In her new role, Kuhl will focus on advancing understanding of Invivyd's work in developing monoclonal antibodies for viral disease prevention and treatment, while building stakeholder trust and supporting company growth. Her appointment comes at a strategic time as Invivyd aims to strengthen its scientific credibility and relationships with key healthcare stakeholders.
Invivyd (Nasdaq: IVVD) announced its participation in two upcoming investor conferences in New York. The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, 2025, at 2:10 PM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 12:00 PM ET.
The presentations will be available via live webcasts on the company's investor website and archived for approximately 30 days. Management will also host investor meetings during both conferences.
Invivyd (Nasdaq: IVVD) has successfully closed its public offering, raising $57.5 million in gross proceeds. The offering included 89.2 million shares of common stock at $0.52 per share and 21.3 million pre-funded warrants at $0.5199 each. The underwriter, Cantor, fully exercised its option to purchase an additional 14.4 million shares.
The financing was led by RA Capital Management and Janus Henderson Investors. Funds will support the VYD2311 clinical program, research in RSV and measles, and advancement of the SPEAR Study Group's efforts regarding Long COVID and COVID-19 Post-Vaccination Syndrome treatments.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
